Last reviewed · How we verify
Rose Bengal
Rose Bengal is a xanthene dye that generates reactive oxygen species upon light activation to destroy targeted cells and tissues.
Rose Bengal is a xanthene dye that generates reactive oxygen species upon light activation to destroy targeted cells and tissues. Used for Ophthalmic use (e.g., age-related macular degeneration via photodynamic therapy), Experimental photodynamic therapy for various cancers and lesions.
At a glance
| Generic name | Rose Bengal |
|---|---|
| Also known as | Corneal Cross Linking with rose Bengal, PV-10 |
| Sponsor | University of California, San Francisco |
| Drug class | Photosensitizer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rose Bengal absorbs light energy and transitions to an excited state, producing singlet oxygen and other reactive oxygen species that cause direct cellular damage and death. It is used primarily in photodynamic therapy (PDT) applications where light activation is applied to the target tissue. The drug accumulates in diseased or neoplastic tissue and, when exposed to appropriate wavelengths of light, induces phototoxic effects leading to tissue destruction.
Approved indications
- Ophthalmic use (e.g., age-related macular degeneration via photodynamic therapy)
- Experimental photodynamic therapy for various cancers and lesions
Common side effects
- Photosensitivity reaction
- Local tissue necrosis at treatment site
- Vision changes or visual disturbances
- Injection site reactions
Key clinical trials
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II (PHASE3)
- Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa (NA)
- PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma (PHASE1, PHASE2)
- A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver (PHASE1)
- A Study to Assess PV-10 Chemoablation of Cancer of the Liver (PHASE1)
- PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma (PHASE3)
- Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rose Bengal CI brief — competitive landscape report
- Rose Bengal updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI